Skip to main content
SpringerLink
Log in

A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin’s lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a serious problem for cancer patients receiving chemotherapy. The CHOP regimen is the standard treatment for non-Hodgkin’s lymphoma (NHL) and is categorized as highly or moderately emetogenic in the CINV guidelines. The efficacy of oral 5-HT3 receptor antagonists is equivalent to that of the intravenous form in patients with solid tumors, but there is no clear comparative data for the use of these agents NHL patients receiving CHOP. We analyzed retrospective CINV data from medical records of 72 NHL patients who received CHOP or rituximab-combined CHOP therapy (R-CHOP). All patients received 5-HT3 receptor antagonists alone for prevention of CINV; 39 of the patients received an intravenous form (mostly granisetron) and 33 an oral form (all ramosetron). Complete response (CR: defined as no vomiting and no rescue therapy) was observed in 58 of 72 patients (80.6 %) overall (0–120 h post-CHOP). The CR rate was not statistically different in patients treated with oral or intravenous 5-HT3 receptor antagonists (82.1 vs 78.8 %, P = 0.77). These findings suggest that oral 5-HT3 receptor antagonists represent a good alternative to intravenous forms in NHL receiving CHOP/R-CHOP chemotherapy. Further studies are needed to identify the optimal anti-emetic supportive therapy for NHL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Japan Society of Clinical Oncology. Guideline: appropriate use of antiemetics version 2.0 (in Japanese). Tokyo: Kanehara & Co., Ltd; 2015.

    Google Scholar 

  2. National Comprehensive Cancer Network (2015) NCCN clinical practice guidelines in oncology: antiemesis version 2. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed Sept 2015.

  3. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2009;21(Suppl 5):v232–43.

    Google Scholar 

  4. Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998;16:1568–73.

    CAS  PubMed  Google Scholar 

  5. Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy–a randomised study. Eur J Cancer. 1993;29A:1669–72.

    Article  CAS  PubMed  Google Scholar 

  6. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998;16:754–60.

    CAS  PubMed  Google Scholar 

  7. Stewart A, McQuade B, Cronje JD, Goedhals L, Gudgeon A, Corette L, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology. 1995;52:202–10.

    Article  CAS  PubMed  Google Scholar 

  8. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115–24.

    Article  CAS  PubMed  Google Scholar 

  9. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  PubMed  Google Scholar 

  10. Jørgensen M, Victor MA. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. Acta Oncol. 1996;35:159–63.

    Article  PubMed  Google Scholar 

  11. Sasai Y, Misawa S, Iwai T, Tamura A, Nakazawa N, Ueda Y, et al. Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin’s lymphoma. Gan To Kagaku Ryoho. 1998;25:723–9 (Japanese).

    CAS  PubMed  Google Scholar 

  12. Yano S, Makino K, Nakamura H, Kai Y, Morioka M, Hamada J, et al. Comparative clinical study of the anti-emetic effects of oral ramosetron and injected granisetron in patients with malignant glioma undergoing ACNU chemotherapy. Neurol Med Chir (Tokyo). 2005;45:294–9.

    Article  Google Scholar 

  13. Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013;104:711–7.

    Article  CAS  PubMed  Google Scholar 

  14. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–30.

    Article  CAS  PubMed  Google Scholar 

  15. McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17–24.

    Article  CAS  PubMed  Google Scholar 

  16. Dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012;104:1280–92.

    Article  PubMed  Google Scholar 

  17. Maie K, Okoshi Y, Takaiwa N, Kurita N, Hasegawa Y, Homma M, et al. Aprepitant does not alter prednisolone pharmacokinetics in patients treated with R-CHOP. Ann Oncol. 2014;25:298–9.

    Article  CAS  PubMed  Google Scholar 

  18. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9:188–95.

    Article  CAS  PubMed  Google Scholar 

  19. Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 2016;24:2381–92

    Article  PubMed  Google Scholar 

  20. Wong EH, Clark R, Leung E, Loury D, Bonhaus DW, Jakeman L, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995;114:851–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008;107:469–78.

    Article  CAS  PubMed  Google Scholar 

  22. Di Renzo N, Montanini A, Mannina D, Dondi A, Muci S, Mancuso S, et al. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin’s lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Support Care Cancer. 2011;19:1505–10.

    Article  PubMed  Google Scholar 

  23. Choi BS, Borsaru GP, Ballinari G, Voisin D, Di Renzo N. Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy. Leuk Lymphoma. 2014;55:544–50.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology/Hematology, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan

    Tsutomu Takahashi, Satoshi Kumanomidou, Saki Takami, Takahiro Okada, Koji Adachi, Yumi Jo, Fumiyoshi Ikejiri, Chie Onishi, Koshi Kawakami, Takaaki Miyake, Masaya Inoue, Ichiro Moriyama, Ritsuro Suzuki & Junji Suzumiya

Authors
  1. Tsutomu Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoshi Kumanomidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saki Takami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takahiro Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koji Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yumi Jo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fumiyoshi Ikejiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chie Onishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Koshi Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takaaki Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masaya Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ichiro Moriyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ritsuro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Junji Suzumiya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Takahashi.

Ethics declarations

Conflict of interest

Authors declare no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 14 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takahashi, T., Kumanomidou, S., Takami, S. et al. A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin’s lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists. Int J Hematol 104, 378–383 (2016). https://doi.org/10.1007/s12185-016-2041-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-016-2041-z

Keywords

Search

Navigation